TP53 and acute myeloid leukemia: To evaluate the potential of established and/or emerging immuno‐oncological drugs to affect T‐cells in TP53‐mutated AML, the expression levels of 12 molecules representing targets for such drugs were examined for the specific T‐cell subpopulations20, 21 (Figure 3).